timothy sykes logo
Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data Thumbnail
G Google News

Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data

MATT MONACO•UPDATED SEP. 5, 2026, 11:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Tenax Therapeutics Inc. stocks have been trading up by 7.87 percent amid heightened optimism from recent clinical development headlines.

Market Insights For Active TENX Traders

  • Additional Phase 3 LEVEL data showed a defined PH-HFpEF subgroup with meaningful gains in exercise capacity, cardiac biomarkers, and pulmonary pressures, shaping a more targeted registrational plan.
  • Full LEVEL data from ESC 2026 confirmed the trial missed primary and key secondary endpoints overall, but a pre‑specified low‑capacity subgroup achieved statistically significant and clinically relevant improvements.
  • Management plans an enriched LEVEL‑2 Phase 3 trial focused on this responder subgroup in PH-HFpEF, where no approved therapies exist, creating a binary-style future catalyst.
  • Leerink slashed its price target from $26 to $4 yet kept an Outperform rating, pointing to lowered expectations but perceived upside from current TENX levels.
  • Guggenheim cut its stance from Buy to Neutral, while the broader Street remains overweight with a mean price target of $9, underscoring a split, volatile setup.

Candlestick Chart

Weekly Update Aug 31 – Sep 04, 2026: On Saturday, September 05, 2026 Tenax Therapeutics Inc. stock [NASDAQ: TENX] is trending up by 7.87%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Tenax Therapeutics (TENX) remains a micro-cap, single-asset pulmonary hypertension play with no revenue, deeply negative ROE (~-60%) and ROA (~-57%), and operating loss of ~$18.8M in Q2 2026 driven by $12.9M R&D. However, the balance sheet is unusually strong for a nano-cap: ~$118M cash versus just ~$8.1M liabilities, current ratio ~15x and no debt, implying multi-year runway at current burn. Shares trade at ~0.6x book (BVPS $3.04), reflecting high clinical and regulatory risk despite solid capitalization.

Technically, TENX is in a short-term uptrend, with the stock lifting from ~$1.76 to ~$1.92 over the week and printing a higher-high/higher-low structure on the daily. Intraday 5-minute action shows strong bids stepping in above $1.80 and supply emerging near $1.95–2.00, with volume expanding on up-moves and drying on pullbacks. The actionable level is $1.80: above this, long bias is warranted; a decisive break below $1.75 would invalidate near-term bullish positioning.

The updated LEVEL Phase 3 data in PH-HFpEF show a failed overall trial but compelling efficacy in a pre-specified low–exercise-capacity subgroup, supporting an enriched LEVEL-2 registrational strategy in a large, untreated niche. Leerink’s cut to $4 and Guggenheim’s downgrade temper expectations but still imply material upside versus ~$2. TENX screens higher risk and more binary than broader Healthcare and Biotech indices; risk-tolerant investors can accumulate between $1.75–2.00 with a 12–18 month fair-value target of $4, resistance $2.50, support $1.50.

More Breaking News

Quick Financial Overview

Tenax Therapeutics Inc. is trading in a tight but active band, with recent weekly closes moving between roughly $1.76 and $1.92. The latest weekly candle shows a push from a $1.94 high to a $1.92 close, holding most intraday gains. Intraday 5‑minute data back that picture: price ran from about $1.815 to $1.955 and settled near $1.94, signaling responsive buying on news rather than a blow‑off spike. For short‑term traders, that kind of controlled strength after volatile news is important.

Under the hood, Tenax Therapeutics Inc. is still a classic development‑stage biotech. The latest quarter shows net income of about -$17.8M and EBITDA near -$18.8M, driven mainly by $12.9M in research spend and $5.9M in general and administrative costs. Cash flow from operations was roughly -$14.2M, but the balance sheet lists about $118.0M in cash and equivalents, plus a current ratio near 15.1 and no debt. That means the company is burning cash but not boxed in by near‑term liabilities.

Valuation ratios show why TENX acts like a speculative vehicle. Book value per share is about $3.04, while price-to-book around 0.59 puts the stock below its accounting equity. At the same time, management effectiveness metrics are deeply negative, with return on equity, assets, and capital solidly below zero — a normal pattern for a pre‑revenue pipeline name but a reminder that everything hangs on TNX‑103 progress. With enterprise value around -$4.95M, the market is basically valuing the cash pile while heavily discounting the pipeline.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”